
Veeva Systems (VEEV) Stock Forecast & Price Target
Veeva Systems (VEEV) Analyst Ratings
Bulls say
Veeva Systems has demonstrated solid growth as evidenced by an increase in net headcount and strong subscription revenue, with notable performance in Crossix and business consulting services, which collectively contribute to a positive outlook. The company has significantly advanced its R&D and Quality Cloud offerings while expanding its customer base, which now includes over 100 emerging biotech clients, further solidifying its market position. Additionally, the company’s impressive guidance for FY27 indicates a projected top-line growth of 12.4% year-over-year and a robust operating margin of 44.3%, underscoring its capability for continued financial success and market share expansion.
Bears say
Veeva Systems faces a negative outlook primarily due to a slight compression in operating margins to 44% amidst a 5% operational decline, coupled with challenges in customer penetration and a competitive landscape in the pharma CRM market. The company is experiencing stagnant year-over-year margins attributed to a shift towards services and hiring investments, which have added to the financial pressure with gross margin headwinds observed in their service offerings. Additionally, a projected slowdown in normalized billings growth to 10-11% further accentuates concerns regarding revenue generation and adoption of new products, ultimately leading to a downward revision of the company's price target.
This aggregate rating is based on analysts' research of Veeva Systems and is not a guaranteed prediction by Public.com or investment advice.
Veeva Systems (VEEV) Analyst Forecast & Price Prediction
Start investing in Veeva Systems (VEEV)
Order type
Buy in
Order amount
Est. shares
0 shares